Highlights

• India’s pharmaceutical industry may double in five years through global partnerships.
• Minister highlights shift from generics to innovation-led pharmaceutical products.
• India records 7.7% growth amid global geopolitical and trade challenges.

India is positioning its pharmaceutical sector for deeper global integration, with Union Commerce and Industry Minister Shri Piyush Goyal inviting international pharmaceutical companies to collaborate with India’s expanding healthcare ecosystem. Speaking at the Global Ambassador Meet on Pharmaceutical Sector and curtain raiser for GDRC 2026 and IPHEX 2026 in New Delhi, he said India’s pharmaceutical industry, currently valued at around USD 60 billion, has the potential to double over the next five years.

The remarks underline India’s evolving role in global healthcare supply chains, as the country transitions from a generics-led market to a more innovation-driven pharmaceutical ecosystem while maintaining its focus on affordable medicines.

Source: Analysis by Kalkine 

India’s Pharmaceutical Expansion Strategy

Shri Goyal emphasized that India is moving beyond its traditional strength in generic medicines toward innovation-led pharmaceutical products. At the same time, he reiterated that affordability remains central to India’s healthcare approach.

He noted that India positions itself as a trusted partner in global pharmaceutical supply chains, functioning not only as a manufacturer but also as a clinical trial destination, technology collaborator, and innovation hub.

The minister highlighted that India remains one of the fastest-growing large economies globally, even amid geopolitical tensions in West Asia and Ukraine, as well as global trade pressures including tariffs imposed by the United States. He stated that India recorded 7.7% growth at constant prices for the year ending March 2026.

Trust, Innovation and Partnerships Framework

Shri Goyal identified three key pillars driving India’s pharmaceutical sector: trust, innovation, and partnerships.

On trust, he noted that India has aligned its Good Manufacturing Practices with global standards. He highlighted that a significant share of global vaccine demand is supplied by India, and several major global generic pharmaceutical firms operate within the country. India also hosts the highest number of US FDA-approved pharmaceutical manufacturing facilities outside the United States.

On innovation, he pointed to nearly 100% growth in patent filings in recent years. The government has introduced initiatives such as Biopharma Shakti and a USD 10 billion innovation support programme across sectors, including pharmaceuticals.

On partnerships, he invited global pharmaceutical companies to expand operations in India, citing its population of 1.4 billion, rising incomes, and expanding middle class as key growth drivers.

India’s Role in Global Healthcare Supply Chains

India continues to play a major role in global medicine supply, particularly in the generic drug segment. According to the minister, India supplies 80–90% of generic medicines by volume in several global markets, though these account for a smaller share of value, reflecting affordability.

He also noted that around 65–70% of World Health Organization vaccine requirements are sourced from India, reinforcing its role as a key global supplier of essential medicines.

India’s trade agreements with more than 50 countries and nine recent free trade agreements have further strengthened market access for pharmaceutical exports.

Policy Direction and Global Cooperation

The minister stated that India is prepared to offer market access to high-quality innovative pharmaceutical products from partner nations, including preferential access under trade agreements.

He emphasized that India’s healthcare philosophy is rooted in the Sanskrit principle “Sarve Santu Niramaya,” meaning universal well-being. This philosophy continues to guide modern healthcare policy and international cooperation.

Referring to the COVID-19 pandemic, he highlighted India’s role in supplying medicines to over 100 countries, including both free supplies and affordable exports, while ensuring domestic availability during crisis conditions.

India’s Position in Global Pharma Landscape

India’s pharmaceutical industry is increasingly being viewed as a hybrid model combining scale manufacturing, cost efficiency, and emerging innovation capacity. The government’s focus on research, patent activity, and global partnerships indicates a gradual shift toward higher-value pharmaceutical segments.

The sector’s expansion is also supported by regulatory alignment with global benchmarks and increasing integration into international supply chains, particularly in vaccines, generics, and active pharmaceutical ingredients.

Key Risks

• Global trade tensions may affect pharmaceutical export demand and pricing stability.
• Rising R&D costs could pressure margins during transition to innovation-led model.
• Regulatory divergence across countries may slow international expansion efforts.
• Dependence on global supply chains may create vulnerability during geopolitical disruptions.

Outlook

India’s pharmaceutical sector is entering a transition phase where scale-driven generics and innovation-led drug development are expected to coexist. Government support, expanding global partnerships, and increasing patent activity suggest a gradual shift toward higher-value healthcare products. However, external geopolitical and trade conditions will continue to influence the sector’s growth trajectory and export performance.

Summary

India is positioning its pharmaceutical industry for significant expansion, with potential to double in value over five years. The government is focusing on innovation, global partnerships, and trust-based manufacturing standards while maintaining affordable medicine supply. With strong export presence and growing R&D activity, the sector is evolving into a more innovation-driven ecosystem, though global trade and regulatory risks remain relevant.

FAQs

Q: What is India’s pharmaceutical industry growth target in coming years?
A: The industry is expected to potentially double in size over the next five years.

Q: What are the main pillars of India’s pharma strategy?
A: Trust, innovation, and partnerships form the core framework guiding sector growth.

Q: How important is India in global medicine supply chains?
A: India supplies a large share of generic medicines and WHO vaccine requirements globally.